A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, a Hypoxia-Activated Prodrug, in Patients With Advanced Leukemias
Tumor hypoxia has been associated with resistance to chemotherapy and radiotherapy (Brown et
al, 2004; Boyle 2006). TH-302, a hypoxia activated prodrug (HAP), exploits the hypoxic
nature of tumors while having little or no effect on normal tissue. TH-302 belongs to a
class of alkylating agents called oxazaphosphorines which have major experimental and
clinical activity (Brock 1989). Since TH-302 is selectively targeted to the hypoxic
microenvironment, this agent may represent an improvement over other agents in this class.
Preclinical data support the hypothesis that TH-302 targets hypoxic regions of tumors and
also is able to kill other tumor cells in normoxic regions as a result of cytotoxin
diffusion, leading to significant effects on tumor growth. Preclinical data has shown that
TH-302 has anti-tumor activity in multiple myeloma cells in vivo and in vitro.
Additional preclinical data demonstrated the marked expansion of the hypoxic bone marrow
areas in diseased mice with ALL. These results suggest that this agent may be useful in
treating advanced leukemias. The drug is stable in plasma and liver, does not appear to be
at risk for drug-drug interactions, and has mild, reversible toxicities. In this
dose-escalation study, patients with advanced leukemias will receive infusions of TH-302 to
determine the maximum tolerated dose.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the maximum tolerated dose of TH-302
2 years
Yes
Marina Konopleva, MD, PhD
Principal Investigator
M.D. Anderson Cancer Center
United States: Food and Drug Administration
TH-CR-407
NCT01149915
June 2010
June 2013
Name | Location |
---|---|
University of Texas M.D. Anderson Cancer Center | Houston, Texas 77030 |